CAJ | 학술논문

目的：探讨胃复方干预治疗对脾虚瘀毒型中晚期胃癌患者生活质量的影响。方法将90例脾虚瘀毒型中晚期胃癌患者随机分为中药联合化疗组、化疗组、中药组,每组30例。中药联合化疗组予胃复方加化疗,化疗组予化疗加安慰剂,中药组予胃复方治疗。观察3组患者QLQ-C30生活质量量表积分、Piper癌因疲乏量表积分、中医证候评分、卡氏评分改变情况及消化道、骨髓抑制毒副反应,评价胃复方对患者生活质量的影响。结果中药联合化疗组QLQ-C30量表积分、癌因疲乏程度、中医证候、体力状况改善情况优于中药组及化疗组,差异均有统计学意义(P＜0.05)；中药组癌因疲乏程度、中医证候改善情况优于化疗组,差异均有统计学意义(P＜0.05)；中药联合化疗组骨髓抑制及消化道毒副反应较化疗组轻,2组比较差异有统计学意义(P＜0.01)。结论胃复方干预治疗能改善脾虚瘀毒型中晚期胃癌患者生活质量,减轻化疗所致骨髓抑制及消化道毒副反应。
목적：탐토위복방간예치료대비허어독형중만기위암환자생활질량적영향。방법장90례비허어독형중만기위암환자수궤분위중약연합화료조、화료조、중약조,매조30례。중약연합화료조여위복방가화료,화료조여화료가안위제,중약조여위복방치료。관찰3조환자QLQ-C30생활질량량표적분、Piper암인피핍량표적분、중의증후평분、잡씨평분개변정황급소화도、골수억제독부반응,평개위복방대환자생활질량적영향。결과중약연합화료조QLQ-C30량표적분、암인피핍정도、중의증후、체력상황개선정황우우중약조급화료조,차이균유통계학의의(P＜0.05)；중약조암인피핍정도、중의증후개선정황우우화료조,차이균유통계학의의(P＜0.05)；중약연합화료조골수억제급소화도독부반응교화료조경,2조비교차이유통계학의의(P＜0.01)。결론위복방간예치료능개선비허어독형중만기위암환자생활질량,감경화료소치골수억제급소화도독부반응。
Objective To evaluate the effect of gastric compound on patients with middle-late gastric cancer of spleen deficiency and stasis toxin. Methods Ninety patients with middle-late gastric cancer of spleen deficiency and stasis toxin were randomly divided into combined group, chemotherapy group, and gastric compound group, 30 cases in each group. Patients in the combined group were treated with gastric compound and chemotherapy;patients in the chemotherapy group were treated with placebo;patients in the gastric compound group were treated with gastric compound. The changes of QLQ-C30 scale integral, fatigue scale intergral, TCM symptom intergral, Karnofsky integral, and toxic and side effects of digestive tract and myelosuppression were observed to evaluate the effect of gastric compound on quality of life in patients. Results The changes of QLQ-C30 scale integral, fatigue scale intergral, TCM symptom intergral, Karnofsky intergal in combined group were better than those in chemotherapy group and gastric compound group, with statistical significance (P<0.05). The changes of fatigue scale intergral and TCM symptom intergral in gastric compound group were better than those in chemotherapy group, with statistical significance (P<0.05). The myelosuppression and toxic and side effects of digestive tract of combined group was lighter than those of chemotherapy group, with statistical significance (P<0.01). Conclusion Gastric compound combined with chemotherapy can improve quality of life in patients with middle-late gastric cancer of spleen deficiency and stasis toxin, and reduce myelosuppression and toxic and side effects of digestive tract.